Association between the metabotropic glutamate receptor7 rs3749380 polymorphism and methylphenidate treatment outcome in children with ADHD

Amaç: Dikkat eksikliği hiperaktivite bozukluğu (DEHB) dikkatsizlik, dezorganizasyon ve/veya hiperaktivite-dürtüsellik ile kararkterize kalıtsal bir nörogelişimsel bozukluktur. Bu çalışmada, Koreli DEHB'li çocuklarda metabotropik glutamat reseptör (GRM) 7 rs3749380 polimorfizm genotipleri ile metilfenidata (MPH) öznel/nesnel tedavi yanıtları arasındaki ilişki araştırılmıştır. Yöntem: Çalışmaya sekiz haftalık açık etiketli MPH çalışmasındaki ilaç kullanmayan DEHB'li 86 çocuk alındı. Deneklerin genotipleri çalışıldı ve sonra tedavi öncesinde ve sonrasında DEHB Değerlendirme Ölçeği (ARS), Sürekli Performans Testi (CPT) ve Genel Klinik İzlenim Ölçeği (CGI) ile değerlendirildi. Sonuçlar: Sekiz haftalık MPH kullanılmasından sonra GRM7 rs3749380 polimorfizm T/T genotipindeki çocuklar CPT'de C/C veya C/T genotip grubundakilerden görsel yanıt süreleri ve işitsel görev hatalarıyla ilgili olarak farklı bir yanıta sahipti. Tartışma: Bu sonuçlar GRM7 rs3749380 polimorfizminin DEHB'li hastalarda MPH'ye yanıtla ilişkili olduğunu düşündürür. Bir kontrol veya karşılaştırma grubu ve daha büyük bir örneklem kullanarak bulgularımızın replikasyonunu içeren ileri çalışmalar, GRM7 genleri ile DEHB'li deneklerde MPH'ye tedavi yanıtları arasındaki ilişkiyi değerlendirmeye olanak sağlayacaktır.

DEHB'li çocuklarda metabotropik glutamat reseptör7 rs3749380 polimorfizmi ile metilfenidat tedavi sonuçları arasındaki ilişki

Objective: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder characterized by inattention, disorganization, and/or hyperactivity-impulsivity. This study investigated the association between the metabotropic glutamate receptors (GRM) 7 rs3749380 polymorphism genotypes and subjective/objective treatment responses to methylphenidate (MPH) in Korean children with ADHD. Methods: This study enrolled 86 medicationnaïve children with ADHD in an open-label 8-week trial of MPH. The subjects were genotyped and then evaluated using the ADHD Rating Scale (ARS), the Continuous Performance Test (CPT) and the Clinical Global Impression Scale (CGI) before and after treatment. Results: After 8-week MPH treatment, children with the GRM7 rs3749380 polymorphism T/T genotype had a different response in terms of visual response times and auditory commission errors on the CPT than C/C or C/T genotype groups. Conclusions: These results suggest that the GRM7 rs3749380 polymorphism is associated with the response of MPH in patients with ADHD. Further studies, including replication of our findings using a control or comparison group and a larger sample, are warranted to evaluate the association between the GRM7 genes and treatment responses to MPH in subjects with ADHD.

___

Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2:104-113.
Konaras K, Neufang S, Hanisch C, Fink GR, Herpertz-Dahlmann B. Dysfunctional attentional networks in children with attention deficit/hyper- activity disorder: evidence from an event-related functional magnetic resonance imaging study. Biol Psychiatry 2006; 59:643-651.
Lijffijt M, Kenemans JL, Verbaten MN, van Enge- land H. A meta-analytic review of stopping perfor- mance in attention-deficit/hyperactivity disorder: deficient inhibitory motor control? J Abnorm Psychol 2002; 114:216-222.
Martinussen R, Hayden J, Hogg-Johnson S, Tannock R. A meta-analysis of working memory impairments in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:377-384.
Nigg JT, Blaskey LG, Huang-Pollock CL, Rappley MD. Neuropsychological executive functions and DSM-IV ADHD subtypes. J Am Acad Child Adolesc Psychiatry 2002; 41:59-66.
Nigg JT, Casey BJ. An integrative theory of attention-deficit/ hyperactivity disorder based on the cognitive and affective neurosciences. Dev Psychopathol 2005; 17:785-806.
Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 2005; 57:1336-1346.
Poelmans G, Pauls DL, Buitelaar JK, Franke B. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry 2011; 168:365-377.
Stergiakouli E, Hamshere M, Holmans P, Langley K, Zaharieva I, De CG, et al. Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. Am J Psychiatry 2012; 169:186-194.
Willliams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R. et al. Rare chro- mosomal deletions and duplications in attention- deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010; 376:1401-1408.
Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradre- naline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011; 69:e145-157.
Gizer IR, Ficks C, Waidman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009; 126:51-90.
Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003; 140:1-47.
Nakanishi S. Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron 1994; 13:1031-1037.
Courvosie H, Hooper SR, Fine C, Kwock L, Castil- lo M. Neurometabolic functioning and neuro- psychological correlates in children with ADHD-H: preliminary findings. J Neuropsychiatry Clin Neurosci 2004; 16:63-69.
Turic D, Langley K, Mills S, Sthephens M, Lawson D, Govan C. et al. Follow-up of genetic linkage findings on chromosome 16p13: evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry 2004; 9:169-173.
Nakanishi S, Nakajima Y, Masu M, Ueda Y, Naka- hara K, Watanabe D, et al. Glutamate receptors: brain function and signal transduction. Brain Res Brain Res Rev 1998; 26:230-235.
Williams NM, Bowen T, Spurlock G, Norton N, Williams HJ, Hoogendoorn B, et al. Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the N-methyl-D-aspartate glutamate receptor. Mol psychiatry 2002; 7:508-514.
Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 72:29-39.
Ohtsuki T, Koga M, Ishiguro H, Horiuchi Y, Arai M, Niizato K, et al. A polymorphism of the meta- botropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr Res 2008; 101:9-16.
Flor PJ, Van Der Putten H, Ruegg D, Lukic S, Leonhardt T, Bence M, et al. A novel splice variant of a metabotropic glutamate receptor, human mGluR7b. Neuropharmacology 1997; 36:153- 159.
Kinoshita A, Shigemoto R, Ohishi H, van der Putten H, Mizuno N. Immunohistochemical locali- zation of metabotropic glutamate receptors, mGluR7a and mGluR7b, in the central nervous system of the adult rat and mouse: a light and electron microscopic study. J Comp Neurol 1998;
Kosinski CM, Risso Bradley S, Conn PJ, Levey AI, Landwehmeyer GB, Penney JB Jr., et al. Locali- zation of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J Comp Neurol 1999; 415:266-284.
Callaerts-Vegh Z, Beckers T, Ball SM, Baeyens F, Callaerts PF, Cryan JF, et al. Concomitant deficits in working memory and fear extinction are func- tionally dissociated from reduced anxiety in meta- botropic glutamate receptor 7-deficient mice. J Neurosci 2006; 26:6573-6582.
Cryan JF, Kelly PH, Neijt HC, Sansis G, Flor PJ, van der Putten H. Antidepressant and anxiolytic- like effects in mice lacking the group III metabotro- pic glutamate receptor mGluR7. Eur J Neurosci 2003; 17:2409-2417.
Fendt M, Schmid S, Thakker DR, Jacobson LH, Yamamoto R, Mitsukawa K, et al. mGluR7 facili- tates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatry 2008; 13:970- 979.
Masugi M, Yokoi M, Shigemoto R, Muguruma K, Watanabe Y, Sansis G.et al. Metabotropic gluta- mate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion. J Neurosci 1999; 19:955-963.
Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP, et al. Meta-analysis of genome-wide association studies of attention- deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010; 49:884-897.
Mick E, Neale B, Middleton FA, Mcgough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. J Med Genet B Neuropsychiatr Genet 2008; 147B:1412- 1418.
Rubia K, Halari R, Christakou A, Taylor E. Impul- siveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity dis- order during temporal processes and normaliza- tion with methylphenidate. Philos Trans R Soc Lond B Biol Sci 2009; 364:1919-1931.
Kobel M, Bechtel N, Weber P, Specht K, Klarhofer M, Scheffeler K, et al. Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 2009; 13:516-523.
Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E. Methylphenidate nor- malises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuro- pharmacology 2009; 57:640-652.
American Psychiatric Association. Diagnostic Criteria from DSM-IV-TR. Washington, D.C.: American Psychiatric Association, 2000.
Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie- Schedule for Affective Disorders and Schizo- phrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004; 45:81-89.
Kim BN, Cummins TD, Kim JW, Bellgrove MA, Hong SB, Song SH, et al. Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val(6) (6)Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children. Int J Neuropsychopharmacol 2011; 14:1399-1410.
Cheon KA, Cho DY, Koo MS, Song DH, Namkoog K. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperacti- vity disorder. Biol Psychiatry 2009; 65:564-570.
Ganda C, Schwab SG, Amir N, Heriani H, Irmans- yah I, Kusumawardhani A, et al. A family-based association study of DNA sequence variants in GRM7 with schizophrenia in an Indonesian population. Int J Neuropsychopharmacol 2009;
Shibata H, Tani A, CHikuhara T, Kikut R, Sakai M, Ninimiya H, et al. Association study of poly- morphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizo- phrenia. Psychiatry Res 2009; 167:88-96.
Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, et al. Predictors of treatment outcome in adults with ADHD treated with OROS(R) methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:554-560.
Tamm L, Trello-rishel K, Riggs P, Nakonezny Pa, Acosta M, Bailey G, et al. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. J Subst Abuse Treat 2013; 44:224-230.
Doyle AE, Faraone SV, Seidman LJ, Willcutt EG, Nigg JT, Waldman ID, Et al. Are endophenotypes based on measures of executive functions useful for molecular genetic studies of ADHD? J Child Psychol Psychiatry 2005; 46:774-803.